English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background: Tumours are diverse ecosystems with persistent heterogeneity invarious cancer hallmarks like self-sufficiency of growth factor production forangiogenesis and reprogramming of energy-metabolism for aerobic glycolysis.This heterogeneity has consequences for diagnosis, treatment, and diseaseprogression.  Methods: We introduce the double goods game to study the dynamics of thesetraits using evolutionary game theory. We model glycolytic acid production as apublic good for all tumour cells and oxygen from vascularization via VEGFproduction as a club good benefiting non-glycolytic tumour cells. This resultsin three viable phenotypic strategies: glycolytic, angiogenic, and aerobicnon-angiogenic.  Results: We classify the dynamics into three qualitatively distinct regimes:(1) fully glycolytic, (2) fully angiogenic, or (3) polyclonal in all three celltypes. The third regime allows for dynamic heterogeneity even with lineargoods, something that was not possible in prior public good models thatconsidered glycolysis or growth-factor production in isolation.  Conclusion: The cyclic dynamics of the polyclonal regime stress theimportance of timing for anti-glycolysis treatments like lonidamine. Theexistence of qualitatively different dynamic regimes highlights the ordereffects of treatments. In particular, we consider the potential of vascularrenormalization as a neoadjuvant therapy before follow up with interventionslike buffer therapy.

Cancer treatment scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and vasculature